Allakos (ALLK) shares were over 45% higher in recent premarket trading Wednesday after the company said it has entered into a definitive agreement to be acquired by Concentra Biosciences.
Under the merger agreement, a Concentra subsidiary will start a tender offer to acquire all outstanding shares of Allakos for $0.33 per share in cash by April 15.
The transaction is expected to close in May, Allakos said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.